CJC-1295 + Ipamorelin: The Complete Research Guide

Introduction to the GH Axis

The growth hormone (GH) axis is a complex neuroendocrine system regulated by two primary hypothalamic hormones: growth hormone-releasing hormone (GHRH), which stimulates GH release, and somatostatin, which inhibits it. GH secretagogues and GHRH analogues represent important research tools for studying this system.

CJC-1295 and ipamorelin are two compounds that act on complementary pathways within this axis, and are frequently studied in combination for their synergistic effects.

CJC-1295: A GHRH Analogue

CJC-1295 is a synthetic analogue of GHRH(1-29) — the biologically active fragment of growth hormone-releasing hormone. Native GHRH has a very short half-life due to rapid degradation by proteases. CJC-1295 incorporates modifications to resist enzymatic breakdown and extend its duration of action.

In research models, CJC-1295 has been shown to increase plasma GH levels and subsequently elevate IGF-1 levels in a sustained manner. The compound acts directly on pituitary somatotroph cells via the GHRH receptor.

Research applications include:

• —Studies of pituitary function and GHRH receptor pharmacology
• —Investigation of the GH/IGF-1 axis in aging and body composition models
• —Combination studies with GH secretagogues

Ipamorelin: A Selective GH Secretagogue

Ipamorelin is a pentapeptide GH secretagogue that activates the ghrelin receptor (GHS-R1a) in the pituitary and hypothalamus. It was developed specifically for its highly selective GH-releasing properties.

A key characteristic of ipamorelin in research is its selectivity profile. Unlike earlier GH secretagogues such as GHRP-6, ipamorelin demonstrates minimal effect on cortisol, prolactin, or ACTH release at GH-stimulating doses, making it a cleaner research tool for studying GH-specific effects.

The Combination Approach

CJC-1295 and ipamorelin act on distinct but complementary receptors:

• —CJC-1295 acts on the GHRH receptor, amplifying the magnitude of GH pulses
• —Ipamorelin acts on the ghrelin receptor, increasing the frequency and amplitude of GH release while also suppressing somatostatin tone

Research has demonstrated that this combination produces synergistic GH release exceeding either compound alone. This makes the CJC-1295 + ipamorelin combination a valuable model for studying maximal physiological GH stimulation.

Research in Canada

Popular Peptides supplies CJC-1295 + Ipamorelin (10mg) as a combined research-grade compound, independently tested for purity and identity.

Important Notice

For research use only. Not approved for human or veterinary therapeutic application.

Where to get these

Compounds referenced in this guide:

• —**CJC-1295 + Ipamorelin**

Everything below ships domestically from Vancouver, BC — tracked, insured, discreetly packaged, typically 2 to 5 business days. Nothing crosses a border, so nothing gets held at one. Purity and identity are confirmed per batch by an independent lab, and you can pull the certificate for your exact vial by lot number. Canadian dollars, free shipping over $300 CAD.

Browse every published lab result before you order, or check the reference library for molecular data on each compound.

Frequently asked questions

Why are CJC-1295 and ipamorelin studied together?

They act on separate receptors. CJC-1295 is a GHRH analogue; ipamorelin is a selective ghrelin-receptor secretagogue. The pathways are distinct, which is why the combination is a standing research pairing rather than a redundancy.

Does this use the DAC or no-DAC version of CJC-1295?

The short-acting no-DAC form (Mod GRF 1-29). The difference matters enormously — see our DAC vs no-DAC breakdown.

Why is ipamorelin preferred over GHRP-6 in newer protocols?

Selectivity. Ipamorelin was developed to minimise activity outside the intended pathway, whereas GHRP-6 has well-documented appetite-stimulating activity.